Skip to main content

Table 3 Outcomes for screening, screening + vaccination (base case) for Chilean girls aged 11 years (undiscounted)

From: Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model

  N n (%)a
No vaccinationb HPV-16/18 vaccinec HPV-6/11/16/18 vaccinec
Incident cases of genital warts 4813 4813 (100%) 1445 (30.0%)
Incident cases of CIN1 6249 3100 (49.6%) 2727 (43.6%)
Incident cases of CIN23 1754 691 (39.4% ) 881 (50.2% )
Incident cases of cervical cancer 1370 198 (14.5%) 300 (21.9 %)
Incident cases of cervical cancer deaths 722 104 (14.4%) 158 (21.9 %)
LY 8725602 8738561 8737415
QALY 8723071 8738044 8736841
Total treatment and follow-up related costsd 94208827 39776161 (42.2%) 43413777 (46.1%)
   Screening 24878067 25085155 (100.8%) 25102940 (100.9%)
   CIN1 treatment 10223106 5071376 (49.6%) 4461609 (43.6%)
   CIN23 treatment 2869923 1130504 (39.4%) 1441268 (50.2%)
   Genital warts 396244 396334 (100.0%) 118954 (30.0%)
   Cervical cancer 55841487 8092792 (14.5 %) 12289006 (22.0 %)
Vaccination costsd   7044117 7044117
Net total costsd 94208827 46820278 (49.7%) 50457894 (53.6%)
  1. aPercentage of no vaccination scenario; bScreening alone scenario; cScreening plus vaccination scenarios; dAll costs are presented in 2010 United States dollars.
  2. Note: CIN: cervical intraepithelial neoplasia; LY: life years; QALY: quality-adjusted life years.